NCT03092544View on ClinicalTrials.gov

Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients

PHASE4UnknownINTERVENTIONAL

Enrollment

57

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Multiple Sclerosis

Interventions

DRUG

dimethyl fumarate

Active drug

Trial Locations (1)

12110

Multiple Sclerosis Center of Northeastern New York, Latham

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

Biogen

INDUSTRY

lead

Multiple Sclerosis Center of Northeastern New York

OTHER